Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please provide a link showing any particular group is selling
It’s hard not to think that isn’t the best conclusion.
The suspense builds!
Fortunately or unfortunately soc is not that great
Thanks again for an awesome post! Totally destroys that ridiculous argument
Awesome post!
Oh sure in the little old community hospital in the back water of Mass
And I would imagine those who know this are taking advantage of this
Very good post! Keep the shorts on edge!
“ https://www.statnews.com/2020/11/19/who-recommends-against-remdesivir-covid-19/”
Even the WHO understands your wrong about remdesivir effectiveness! Lol
There not the only ones beclowning themselves!
https://www.statnews.com/2020/11/19/who-recommends-against-remdesivir-covid-19/
Wow! Even The Who doesn’t recommend remdesivir!
Fast track for B!
SI 426 B for covid!
Phase 2 B for covid!
Exciting times!
Pick up shares now!
Did you see the peer reviewed article?
Imagine if ipix had put that out on a pr. What do you think the badgers would say?
Yes I agree!
But does it change the basic science of B against covid?
What you meant to say is non-inferior
No it really doesn’t! It was excepted and published in peer reviewed journal. Period
“ IPIX was involved in the conceptualization, methodology, analysis, data curation, writing, editing, and project administration. None of this is revealed in the "Author Contributions" section of the pre-print. ” How does your breathless revaluation effect the the science? Answer it doesn’t
Up to bat 0-2! Lung tissue and peer review! Keep moving goal post!
Holy cow! We have been discussing the preprint v peer review for weeks now!
Nice catch! Kind of blows up the argument made by some old guy here!
Lol! The nejm is joke! The pre-print came out along time ago but again great call.
What happened to your “where’s the peer reviewed article?” Probably same place human tissue failed argument! 0-2
The Enthusiasts who is running the Twitter account is only reposting the prs and liking some other posts. Pretty innocent stuff.
Of course you didn’t because it wasn’t! But unfortunately that’s not a popular sentiment with some here.
Leo said the trial would start so why should he say it’s delayed lol?!
Can you provide a link please
Yep gap up then lay the hammer down. Can’t wait to get off the otc market
Awesome post. I would imagine that the medical community will be very excited about B!
The game is called “move/change the goal posts” it never ends.
Is that business days
Here is another short article
https://www.zerohedge.com/markets/naked-short-selling-truth-much-worse-you-have-been-told
Awesome! Looks like they were trying to just improve remdesivir lol!
The bar for good therapeutics for covid are very low and how many therapeutics do you know have the extensive preclinical success that B has had?
That’s one of the reason Leo wanted to have an international component to the trial! Go Leo!
Hey Doc take a look at big pharma clinical success rate and remember B has never failed a trial yet!
Pfizer has reported (PDF) a sharp rise in its clinical trial success rate. The Big Pharma put its end-to-end success rate through 2020 at 21%, well up from the 9% it reported just last year.
Historically, Pfizer’s clinical research success rate has lagged behind those of its peers. In 2015, Pfizer calculated that just 5% of its assets that entered first-in-human studies went on to win approval, compared to an industrywide success rate of 11%. Pfizer reported an improvement at its investor day last year, claiming its success rate through 2019 was 9% versus an industry average of 8%.
Now, Pfizer has claimed a major jump in its success rate. In conjunction with its full-year financial results, Pfizer said its success rate through 2020 was 21%. Pfizer is yet to calculate the industrywide average through 2020, but the figure is well up on the performance of its peers through 2019
No clay trader